Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT05052528 · RECRUITING
Trial details
- NCT number
- NCT05052528
- Sponsor
- University of California, Davis
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-17
- Primary completion
- 2027-05-15
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.